Short

Covid funding p&d

This company has not done anything noteworthy for the last few years. They were able to get funding from the European International Bank to work on COVID related solutions released in 3 tranches. The likely outcome is they will not make enough progress to unlock the future tranches. Seems to me like they are just grabbing the handout and will resume their normal downtrend in the long term.
biotechCoronavirus (COVID-19)covid-19cTrend Analysisvaccine

Disclaimer